Revolution Medicines has established a deep pipeline of programs targeting critical signaling nodes within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways.


RMC-4630, a potent and selective inhibitor of SHP2, is currently in a multi-cohort Phase 1/2 clinical program for a range of tumor types.

Read more

We believe our mutant-selective RAS inhibitors are the first potent, selective, cell-active inhibitors of the active, GTP-bound forms of RAS, or RAS(ON).

Read more

We believe that inhibition of SOS1 may represent a viable approach for targeting RAS-driven tumors.

Read More

RMC-5552, a potent and selective inhibitor of mTORC1, is designed to prevent inactivation of the tumor suppressive properties of the 4EBP1 protein.

Read More


Select program assets may be considered for partnership. The opportunity includes our 4EBP1/mTORC1 program and development candidate RMC-5552, which has demonstrated promising preclinical activity.

Contact us